Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases.
AngioChem is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.
Bharat Srinivasa, Principal at Amplitude Venture Capital
Investment year: 2005
Industry sector: Drugs